Future of medicare immunosuppressive drug coverage for kidney transplant recipients in the United States

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 7, 2013, Pages 1258-1266

  Tanriover, Bekir ^a,b   Stone, Patricia W ^c   Mohan, Sumit ^a,b   Cohen, David J ^a   Gaston, Robert S ^d,e  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Columbia University Renal Epidemiology ^*  (United States)

^c Columbia University School of Nursing ^*  (United States)

^d University of Alabama at Birmingham   (United States)

^e Immediate Past President   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; HECORIA; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEALTH INSURANCE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEDICARE; MEDICOLEGAL ASPECT; PATIENT ATTITUDE; PRESCRIPTION; QUALITY OF LIFE; UNITED STATES;

DRUG COSTS; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MEDICARE; PATIENT PROTECTION AND AFFORDABLE CARE ACT; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879832653     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09440912     Document Type: Article

References (33)

1. Nevins TE, Kruse L, Skeans MA, ThomasW: The natural history of azathioprine compliance after renal transplantation. Kidney Int 60: 1565-1570, 2001.
2. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. AmJ Transplant 12: 388-399, 2012.
3. Sanders CE, Curtis JJ, Julian BA, Gaston RS, Jones PA, Laskow DA, Deierhoi MH, Barber WH, Diethelm AG: Tapering or discontinuing cyclosporine for financial reasons-a single-center experience. Am J Kidney Dis 21: 9-15, 1993.
4. De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, Vanrenterghem Y: Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 59: 340-347, 1995.
5. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD: Patient noncompliance: A major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 20[Suppl 3]: 63-69, 1988.
6. Chisholm MA: Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 62: 567-575, 2002.
7. Kory L: Nonadherence to immunosuppressive medications: A pilot survey of members of the transplant recipients international organization. Transplant Proc 31[4A]: 14S-15S, 1999.
8. Kennedy J, Erb C: Prescription noncompliance due to cost among adults with disabilities in the United States. Am J Public Health 92: 1120-1124, 2002.
9. Gaston RS, Hudson SL, Ward M, Jones P, Macon R: Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 31[4A]: 21S-23S, 1999.
10. Gill JS, Tonelli M: Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. N Engl J Med 366: 586-589, 2012.
11. Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011, HR 2969, 112th Cong, 1st sess, 2011. Available at: http://www.govtrack.us/congress/bill.xpd?bill=h112-2969. Accessed August 4, 2012.
12. Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011, S 1454, 112th Cong, 1st sess, 2011. Available at: http://www.govtrack.us/congress/bill.xpd?bill=s112-1454. Accessed August 4, 2012.
13. Social Security Amendments of 1972, P.L. No. 92-603, 86 Stat. 1463, 42 USC section 426(e)(3), 1974.
14. Gaston RS: Appendix D, Part 2; Transplantation and immunosuppressive medications: Evolution of Medicare Policy involving transplantation and immunosuppresive medications-past developments and future directions. In: Extending Medicare Coverage for Preventive and Other Services, edited by Field MJ, Lawrence RL, Zwanziger L, Washington, DC, National Academy Press, 2000, pp 347-362.
15. Centers for Medicare & Medicaid Services: Medicare & You 2013. Available at: http://www.medicare.gov/Publications/Pubs/pdf/10050.pdf. Accesed August 4, 2012.
16. Morrison L: Medicare from A to D: What every nephrologist needs to know. Clin J Am Soc Nephrol 3: 899-904, 2008.
17. US Renal Data System. USRDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the US. Bethesda, MD., National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, 2012, pp 283-294.
18. Sharp LA: A medical anthropologist's view on posttransplant compliance: The underground economy of medical survival. Transplant Proc 31[4A]: 31S-33S, 1999.
19. Sharp LA: Organ transplantation as a transformative experience: Anthropological insights into the restructuring of the self. Med Anthropol Q 9: 357-389, 1995.
20. United States Census Bureau: United States Census Bureau Website. Available at: http://www.census.gov/hhes/www/income/income.html. Accessed on August 4th, 2012.
21. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC: A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 80: 41-46, 2005.
22. Evans RW, Applegate WH, Briscoe DM, Cohen DJ, Rorick CC, Murphy BT, Madsen JC: Cost-related immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol 5: 2323-2328, 2010.
23. Gordon EJ, Prohaska TR, Sehgal AR: The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin Transplant 22: 738-748, 2008.
24. Woodward RS, Schnitzler MA, Lowell JA, Spitznagel EL, Brennan DC: Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants. Am J Transplant 1: 69-73, 2001.
25. Field MJLR, Zwanziger L, editors: Extending Medicare Coverage for Preventive and Other Health Services, Washington, DC, Institute of Health, 2000.
26. US Renal Data System: USRDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the US, Vol. 2, Bethesda,MD, National Institutes of Health,National Institute of Diabetes, Digestive and Kidney Diseases, 2012, pp 215-228.
27. US Renal Data System: USRDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the US, Vol. 2, Bethesda,MD, National Institutes of Health,National Institute of Diabetes, Digestive and Kidney Diseases, 2012, pp 329-340.
28. Yen EF, Hardinger K, Brennan DC, Woodward RS, Desai NM, Crippin JS, Gage BF, Schnitzler MA: Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 4: 1703-1708, 2004.
29. Page TF, Woodward RS: Cost of lifetime immunosuppression coverage for kidney transplant recipients. Health Care Financ Rev 30: 95-104, 2008.
30. Gustafsson L, Bowman J, Taira M: Extendeding Medicare Coverage of Immunosuppressive Drugs for Beneficiaries with ESRD, Washington, DC, Avalere Health LLC, 2005.
31. Axelrod DA, Millman D, Abecassis DD: US Health Care Reform and Transplantation. Part I: Overview and impact on access and reimbursement in the private sector. Am J Transplant 10: 2197-2202, 2010.
32. Becker BN: A conflict of responsibility: No patient left behind. Clin J Am Soc Nephrol 5: 744-745, 2010.
33. Cohen DJ, Murphy B: Drug coverage for transplantation turns into political football: Big business trumps patients. Clin J AmSoc Nephrol 5: 746-747, 2010